Logo image of UBX

UNITY BIOTECHNOLOGY INC (UBX) Stock Fundamental Analysis

NASDAQ:UBX - Nasdaq - US91381U2006 - Common Stock - Currency: USD

0.2001  -0.1 (-33.41%)

After market: 0.1754 -0.02 (-12.34%)

Fundamental Rating

1

Taking everything into account, UBX scores 1 out of 10 in our fundamental rating. UBX was compared to 556 industry peers in the Biotechnology industry. UBX has a bad profitability rating. Also its financial health evaluation is rather negative. UBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year UBX has reported negative net income.
In the past year UBX has reported a negative cash flow from operations.
UBX had negative earnings in each of the past 5 years.
UBX had a negative operating cash flow in each of the past 5 years.
UBX Yearly Net Income VS EBIT VS OCF VS FCFUBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -90.63%, UBX is doing worse than 73.12% of the companies in the same industry.
Industry RankSector Rank
ROA -90.63%
ROE N/A
ROIC N/A
ROA(3y)-55.15%
ROA(5y)-54.83%
ROE(3y)-206.62%
ROE(5y)-167.01%
ROIC(3y)N/A
ROIC(5y)N/A
UBX Yearly ROA, ROE, ROICUBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

UBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UBX Yearly Profit, Operating, Gross MarginsUBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

UBX has more shares outstanding than it did 1 year ago.
UBX has more shares outstanding than it did 5 years ago.
UBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UBX Yearly Shares OutstandingUBX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
UBX Yearly Total Debt VS Total AssetsUBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

UBX has an Altman-Z score of -26.49. This is a bad value and indicates that UBX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -26.49, UBX is not doing good in the industry: 88.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.49
ROIC/WACCN/A
WACCN/A
UBX Yearly LT Debt VS Equity VS FCFUBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

UBX has a Current Ratio of 1.95. This is a normal value and indicates that UBX is financially healthy and should not expect problems in meeting its short term obligations.
UBX has a Current ratio of 1.95. This is in the lower half of the industry: UBX underperforms 76.52% of its industry peers.
UBX has a Quick Ratio of 1.95. This is a normal value and indicates that UBX is financially healthy and should not expect problems in meeting its short term obligations.
UBX has a worse Quick ratio (1.95) than 74.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.95
UBX Yearly Current Assets VS Current LiabilitesUBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

UBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.94%, which is quite impressive.
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

UBX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.84% yearly.
Based on estimates for the next years, UBX will show a very negative growth in Revenue. The Revenue will decrease by -16.43% on average per year.
EPS Next Y4.15%
EPS Next 2Y17.45%
EPS Next 3Y13.8%
EPS Next 5Y15.84%
Revenue Next Year-100%
Revenue Next 2Y-53.8%
Revenue Next 3Y-19.92%
Revenue Next 5Y-16.43%

3.3 Evolution

UBX Yearly Revenue VS EstimatesUBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2022 2024 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
UBX Yearly EPS VS EstimatesUBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UBX. In the last year negative earnings were reported.
Also next year UBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UBX Price Earnings VS Forward Price EarningsUBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UBX Per share dataUBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

UBX's earnings are expected to grow with 13.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.45%
EPS Next 3Y13.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNITY BIOTECHNOLOGY INC

NASDAQ:UBX (7/8/2025, 8:00:01 PM)

After market: 0.1754 -0.02 (-12.34%)

0.2001

-0.1 (-33.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-22 2025-04-22/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners17.19%
Inst Owner Change-6.51%
Ins Owners1.57%
Ins Owner Change7.63%
Market Cap3.44M
Analysts77.5
Price Target3.06 (1429.24%)
Short Float %3.27%
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.38%
Min EPS beat(2)-22.33%
Max EPS beat(2)-6.44%
EPS beat(4)2
Avg EPS beat(4)3.37%
Min EPS beat(4)-22.33%
Max EPS beat(4)33.56%
EPS beat(8)6
Avg EPS beat(8)17.28%
EPS beat(12)10
Avg EPS beat(12)18.78%
EPS beat(16)12
Avg EPS beat(16)18.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.69%
PT rev (3m)-40%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-27.66%
EPS NY rev (1m)-18.24%
EPS NY rev (3m)-12.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.15%
ROA(5y)-54.83%
ROE(3y)-206.62%
ROE(5y)-167.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.95
Altman-Z -26.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1.78%
Cap/Depr(5y)6.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.47%
EPS Next Y4.15%
EPS Next 2Y17.45%
EPS Next 3Y13.8%
EPS Next 5Y15.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-53.8%
Revenue Next 3Y-19.92%
Revenue Next 5Y-16.43%
EBIT growth 1Y21.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.3%
EBIT Next 3Y-7.08%
EBIT Next 5YN/A
FCF growth 1Y54.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.8%
OCF growth 3YN/A
OCF growth 5YN/A